{"id":"W2990041408","doi":"10.1056/nejmoa1913662","title":"Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC","year":2019,"lang":"en","type":"article","venue":"New England Journal of Medicine","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":2816,"is_retracted":false,"has_abstract":true,"ca_institutions":"William Osler Health System; University of Toronto","funders":"AstraZeneca","keywords":"Osimertinib; T790M; Medicine; Oncology; Epidermal growth factor receptor; Lung cancer; Gefitinib; Internal medicine; Hazard ratio; Progression-free survival; Tyrosine kinase; Cancer research; Overall survival; Cancer; Erlotinib; Receptor; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null}